the aid library

LIST OPTIONS

Filter

3732

Download (190)

View PDF (251)

At Heart, Global Health Draws on Compassion, Solidarity and Justice

Addiss, D. (2018) CC

Download (249)

View PDF (309)

Stratégie de riposte face à la résistance aux antipaludiques en Afrique

World Health Organisation (WHO) (2023) C_WHO

La Stratégie de riposte face à la résistance aux antipaludiques en Afrique est un document technique de sensibilisation qui se fonde sur les bases factuelles les plus solides dont on dispose et vise à réduire au maximum la menace et l’impact de la résistance aux antipaludiques de Plasmodium ... more

Download (997)

View PDF (395)

Indonesia Health Profile 2015 (Part 2/2)

Ministry of Health Republic of Indonesia (2016) C1

Download (992)

View PDF (1310)

Intermittent preventive treatment (IPT) of malaria in pregnancy. Training manual for health providers

Ministry of Health Ghana; Ghana Health Service GHSNMCP (2005) C1

Facilitator's Guide

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (1286)

View PDF (2149)

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

Download (577)

View PDF (978)

Tanzania: HIV Care and Treatment Plan 2003-2008

The William J. Clinton Foundation Ministry of Health, Tanzania (2003) C1

Download (389)

View PDF (593)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (244)

View PDF (253)

The impact of Covid-19 on HIV, TB and Malaria Services and Systems for Health: a Snapshot from 502 health facilities across Africa and Asia

The Global Fund (2021) CC

In 2020, the COVID-19 pandemic impacted the world beyond imagination. To date, it has infected more than 135 million people, killed over 2.9 million people, and is projected to plunge up to 115 million people into extreme poverty.1 As countries have gone into lockdown, gender-based violence has incr... more

External Link

Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses

N. Schoenfeld, W. Haas, E. Richter, et al. (2016) C2

Empfehlungen zur Diagnostik und Therapie nichttuberkulöser Mykobakteriosen des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK) und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP). Schönfeld N et al. Recommendations of the German Central Committee… Pneumolo... more

Download (455)

View PDF (338)

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice
recommended

International Union Against Tuberculosis and Lung Disease (2019) C1

The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens

Download (647)

View PDF (832)

First Ethiopian National Population Based Tuberculosis Prevalence Survey

Ministry of Health and Ethiopian Health and Nutrition Research Institute, Federal Democratic Republic of Ethiopia (2011) C1

Download (420)

View PDF (502)

The impact of myopia and high myopia

World Health Organization (WHO) (2017) C_WHO

Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales, Sydney, Australia 16–18 March 2015

Download (552)

View PDF (511)

Rwanda: GUIDE DE PRISE EN CHARGE DE LA TUBERCULOSE MULTIRESISTANTE

Ministere de la Sante & Rwanda Biomedical Centre (2012) C2

Le présent manuel fournit les directives actualisées à l'intention des médecins, infirmiers et laborantins confrontés à la tuberculose multirésistante (TB-MR). Il remplace la version élaborée en 2007 et s’est enrichi de l’expérience pratique de six années. Il s’appuie sur les recomm... more

Download (126)

View PDF (181)

Population Size Estimation of Female Sex Workers In Tbilisi and Batumi, Georgia 2014

Dr. I. Chikovani; Dr. N. Shengelia; L. Sulaberidze; N. Tsereteli; et al. The Global Fund To fight AIDS, Tuberculosis and Malaria; Curatio International Foundation; Tanadgoma (2014) C2

Study Report August 2014 Curatio International Foundation (CIF) and the Association Tanadgoma would like to acknowledge the financial support provided by GFATM under the project “Establishment of evidence base for national HIV/AIDS program by strengthening of HIV/AIDS surveillance system in t... more

Download (187)

View PDF (218)

Toolkit for research and development of paediatric antiretroviral drugs and formulations

World Health Organization (WHO); Unitaid; Unicef; et al. World Health Organization (WHO); Unitaid; Unicef; et al. (2018) C_WHO

WHO and UNITAID in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group

Download (183)

View PDF (196)

Health at a Glance: Europe 2020

OECD (2020) C1

State of Health in the EU Cycle. With the coronavirus (COVID-19) once again spreading rapidly, and the re-introduction of containment measures to flatten the curve of the epidemic, it is crucial for policymakers to plan effective strategies to re-open their economies to avoid further re-confinement... more

Download (285)

View PDF (238)

Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases

World Health Organization WHO (2022) C_WHO

Skin-related neglected tropical diseases, or “skin NTDs”, are historically neglected because active case detection, individual case management, significant resources and intensive effort are required to control, eliminate and eradicate them. Integrated control and management of skin NTDs offers ... more

Download (6509)

View PDF (2853)

WHO Monographs On Selected Medicinal Plants - Volume 4
recommended

World Health Organization WHO (2009) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (109)

View PDF (95)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya recommended

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice recommended

WHO Monographs On Selected Medicinal Plants - Volume 4 recommended

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice
recommended

WHO Monographs On Selected Medicinal Plants - Volume 4
recommended